title: Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.
abstract: BACKGROUND
  Natural human papillomavirus (HPV) antibody titers have shown protection against subsequent HPV infection, but previous studies were restricted to few HPV genotypes. We examined the association of naturally occurring antibodies against 8 carcinogenic HPV types with subsequent infections.
  
  
  METHODS
  A total of 2302 women enrolled in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study provided blood samples at baseline. Serum samples were tested for antibodies against 8 carcinogenic HPV genotypes (16, 18, 31, 33, 35, 45, 52, and 58) using a multiplex serology assay. We analyzed the relationship between HPV antibodies and HPV infection during 2 years of follow-up among women negative for the specific HPV type at baseline.
  
  
  RESULTS
  Baseline seroprevalence for HPV16 L1 was associated with decreased risk of DNA positivity for HPV16 (odds ratio, 0.39 [95% confidence interval, .18-.86]) at ≥2 follow-up visits. We observed similar but nonsignificant decreased risks for HPV18 and 31. These findings were restricted to women reporting a new sex partner during follow-up. There was no association between baseline seroprevalence and detection of precancer during follow-up.
  
  
  CONCLUSIONS
  Seroprevalence conferred protection against subsequent HPV infection for HPV16 and indicated possible protection for 2 other genotypes, suggesting that this effect is common to several HPV genotypes.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina.
authors.forename: Lauren
authors.initials: L
authors.lastname: Wilson
authors.affiliation: German Cancer Research Center, Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.affiliation: Global Cancer Initiative, Chestertown.
authors.forename: Phillip E
authors.initials: PE
authors.lastname: Castle
authors.affiliation: German Cancer Research Center, Heidelberg, Germany.
authors.forename: Tim
authors.initials: T
authors.lastname: Waterboer
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda.
authors.forename: Vikrant
authors.initials: V
authors.lastname: Sahasrabuddhe
authors.affiliation: Department of Epidemiology Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland.
authors.forename: Patti E
authors.initials: PE
authors.lastname: Gravitt
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda.
authors.forename: Mark
authors.initials: M
authors.lastname: Schiffman
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Wentzensen
mesh_terms: D056704:Adaptive Immunity; D005260:Female; D005838:Genotype; D006801:Humans; D016017:Odds Ratio; D009858:Oncogenic Viruses; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics* / Q000276:immunology*; D030361:Papillomavirus Infections / Q000097:blood / Q000453:epidemiology*; D016036:Seroepidemiologic Studies; D002578:Uterine Cervical Dysplasia / Q000821:virology
keywords: Human papillomavirus; natural immunity; serology